Open-Label Treatment Does Not Require Open Interim Results
In an open-label trial, participants and relevant clinical staff know which treatment has been assigned. That knowledge may be unavoidable when treatments differ visibly or require different procedures. It does not follow that every trial analyst must see how outcomes compare between treatment groups at an interim review. A trial can leave treatment delivery open-label while restricting comparative interim findings to specified roles.
The distinction is important in adaptive trials. Some interim information may be needed to make a design decision, while broad access to arm-wise results could influence trial conduct or reveal information to people who do not need it. Separating those two questions—who knows the assigned treatment, and who can see the interim comparison—makes the information boundary clearer. The restriction is about access to results, not about making an open-label treatment assignment unknown to the people delivering or receiving treatment.
For a two-arm trial, let \(A_i\) denote the treatment assigned to participant \(i\), and let \(X_i\) denote the participant's recorded outcome at an interim look. If the available outcomes in the two arms are summarized by \(\bar{x}_A\) and \(\bar{x}_B\), an interim comparison might include the difference
where \(t\) labels the interim look. A site clinician might know \(A_i\) for each participant under their care but not have access to \(\hat{\Delta}_t\) across the trial. Conversely, a designated independent statistician might receive the treatment assignments and interim outcomes to calculate \(\hat{\Delta}_t\), while other analysts remain separated from that result.
What the Separation Does—and Does Not—Mean
The word blinding can be ambiguous here. It may refer to masking the treatment assignment, or it may be used informally to describe restricting access to interim comparisons. In an open-label trial, the first meaning does not apply to participants and personnel who know their assignments. The second describes an information-control arrangement for specified roles, not a change in the treatment experience.
A useful way to specify the distinction is to describe each role's information. A treating clinician may know a participant's assignment and clinical course. A designated interim analyst may have access to both arms' assignment and outcomes. A separate trial analyst may receive only a pooled summary or data that do not permit the interim contrast to be reconstructed. These roles can coexist in one open-label trial. The titles assigned to roles matter less than the information each role can actually access.
For the separation to work as intended, the trial needs a clear, prospective boundary. The permitted data, analyses, outputs, recipients, and timing should match the planned interim purpose. The people who remain separated from comparative results should not also have another route to reconstruct those results from arm-labelled data, informal reports, or unrestricted analysis outputs. A restriction on a report is not a meaningful restriction if the same comparison can readily be calculated from data already available to its recipients.
This arrangement also does not establish that an adaptive design has controlled error rates. Restricting who sees a result can reduce its circulation, but it does not change the statistical properties of an adaptation that uses the result. If an interim treatment contrast informs a design decision, the design's operating characteristics must still be justified for that decision rule. Access control and statistical validity are related parts of trial conduct, but they answer different questions.
Worked Example: Open-Label Care With a Restricted Interim Contrast
Hypothetical trial. A trial compares two open-label rehabilitation programs. The programs use visibly different schedules, so participants and their treating therapists know which program is assigned. At an interim look, 30 participants have outcomes in each arm. An authorized independent statistician calculates mean improvement of 8.6 points in Program A and 6.9 points in Program B. The trial's designated committee may review the comparative result; the analysts preparing routine recruitment summaries do not receive arm-wise interim outcomes or the contrast.
The estimated interim difference in mean improvement is
The calculation indicates that the observed mean improvement is 1.7 points higher in Program A at this interim look. It does not establish that the programs differ in the population, and it is not a final treatment-effect conclusion. For the access question, the key point is that therapists can know their participants' assigned programs while the routine analysts remain without this across-arm comparison. Treatment delivery is open-label; access to the comparative interim result is restricted.
This distinction depends on the actual information flow. If routine analysts also receive the two arm means, or can calculate them from arm-labelled records, describing them as separated from the result would be inaccurate. Likewise, the fact that an independent statistician calculates the contrast does not mean that no one in the trial is unblinded to interim results.
Why a Pooled Summary Need Not Reveal the Contrast
A simple calculation shows why a pooled summary and a comparative summary are different kinds of information. Suppose the two arms have the same sample size \(n\), and the pooled mean is calculated across all \(2n\) outcomes. Then
This pooled mean identifies the sum of the two arm means, not their difference. The arm contrast is \(\bar{x}_A-\bar{x}_B\). Knowing a sum alone does not determine a difference: many pairs of arm means have the same sum but different contrasts. This is a limited algebraic result, not a guarantee that every pooled data release is safe. Additional information, such as arm labels or other summaries, could allow the contrast to be reconstructed.
Worked Example: Same Pooled Mean, Different Interim Contrasts
Hypothetical interim summaries. There are 20 participants in each of two arms. In one possible set of summaries, the arm means are 10 and 10 units. In another, they are 12 and 8 units. Calculate the pooled mean and contrast in each case.
For the first pair,
For the second pair,
Both pairs give the same pooled mean of 10 units, but their observed contrasts differ by 4 units. Thus, if an analyst receives only the pooled mean and the equal arm sizes, that information does not identify which contrast occurred. If the analyst also receives arm-labelled outcomes or additional summaries that reveal the arm means, the separation may fail. The example demonstrates what one pooled statistic omits; it does not prove that all pooled releases conceal every treatment difference.
Conditions, Diagnostics, and Alternatives
A restricted-access arrangement is most defensible when the trial has a defined reason for the interim analysis and a prespecified account of who needs which information. The statistical task and the access boundary should fit together: a role cannot produce an arm-specific comparison while remaining ignorant of the arm-specific results needed to calculate it. An authorized analyst may therefore need access that other trial analysts do not have. The practical aim is not to claim that nobody knows the interim results, but to limit access to the roles and purposes specified for the design.
Several checks help assess whether the boundary is functioning as intended:
- Check data and outputs. Determine whether people described as separated receive arm-labelled records, arm-wise summaries, or other information sufficient to reconstruct the comparison.
- Check role consistency. A person who prepares a supposedly non-comparative report should not also have unrecorded access to comparative interim results through another task or channel.
- Check the decision route. Confirm that the result goes to the role authorized to use it for the planned interim purpose, rather than being circulated as a general trial update.
- Check the statistical justification separately. Ask whether the planned adaptation and analysis account for use of interim data. A restricted report does not substitute for that justification.
The main alternatives differ in what they conceal and who can act on the information. In fully treatment-masked delivery, participants or relevant personnel do not know assigned treatments; that is not the arrangement described by an open-label trial. With restricted comparative interim access, treatment delivery remains open-label, while comparative interim results are limited to designated roles. With unrestricted comparative access, a wider set of roles can see arm-wise interim results; this may be operationally simpler but exposes more people to the comparison. None of these labels, on its own, establishes that an adaptive analysis is statistically valid.
| Arrangement | Treatment assignment known to treating personnel? | Who sees comparative interim results? | What the label does not establish |
|---|---|---|---|
| Open-label with restricted interim access | Yes | Specified roles | That the adaptive analysis controls error rates |
| Treatment-masked delivery | Not to personnel from whom assignment is masked | Depends on the interim access plan | That all interim results are restricted |
| Open-label with broad comparative access | Yes | A wider set of roles | That broad access is needed or harmless |
The arrangement also has limitations. In an open-label trial, people involved in care know treatment assignments, and a restriction on formal analysis reports does not erase that knowledge. Site-level observations or other available information may also make some differences apparent. Further, a designated analyst who sees comparative results must be able to perform the required analysis, and the trial needs to prevent that role from inadvertently sharing restricted findings beyond its intended recipients. These considerations make precise role descriptions and data boundaries essential; they do not turn an open-label trial into a treatment-masked one.
A Common Mistake
A common mistake is to reason, “The trial is open-label, so the interim analysis is necessarily unblinded to everyone,” or the reverse: “The interim results are restricted, so the trial is blinded.” Both conclusions conflate treatment knowledge with results access. The correction is to ask separately: Who knows each participant's assigned treatment? and Who can see or reconstruct the comparative interim result? The answers can differ across roles in the same trial.
A related error is to treat restricted access as proof that interim findings cannot influence the trial. The restriction may reduce exposure among specified roles, but people who see the result may still use it for the authorized decision, and the adaptation must still be evaluated under its statistical design. Describe the access arrangement accurately, then assess the inferential consequences of the adaptation on their own terms.
Check Your Understanding
Answer each question using the distinction between assigned-treatment knowledge and comparative interim information.
- In an open-label trial, treating clinicians know assignments, but only a designated statistician receives arm-wise interim outcomes. Is the trial treatment-masked? Explain.
- Two equal-sized arms have means of 14 and 10 units, with 25 participants per arm. Calculate the pooled mean and the observed contrast.
- Could an analyst who receives only a pooled mean of 12 units conclude that the two arm means are both 12? Explain what else would be needed.
- Why does restricting access to an interim treatment contrast not, by itself, establish control of the trial's type I error rate?
Solutions. (1) No. The clinicians know assigned treatments, so treatment delivery is open-label; access to the comparative interim result is restricted to specified roles. (2) The pooled mean is \([25(14)+25(10)]/50=600/50=12\) units, and the contrast is \(14-10=4\) units. (3) No. A pooled mean of 12 identifies the average of the two arm means when sizes are equal, not each arm mean separately; the arm means could be 12 and 12, or 14 and 10, among other pairs. (4) The restriction controls who receives information, not the statistical behavior of an adaptation that uses interim results. Error-rate control requires justification for the design and decision rule.